Douglas Kling

Douglas F.
Kling currently works at NewAmsterdam Pharma BV, as Chief Operating Officer from 2021, NewAmsterdam Pharma Holding BV, as Chief Operating Officer from 2021, and NewAmsterdam Pharma Co. NV, as Chief Operating Officer from 2021.
Mr. Kling also formerly worked at The Medicines Co., as Senior Director-Program Management from 2008 to 2009, Reliant Pharmaceuticals LLC, as Director-R&D Project Management from 2000 to 2008, Shionogi USA Holdings, Inc., as Senior Director-Project Management from 2009 to 2010, Omthera Pharmaceuticals, Inc., as Senior Vice President-Clinical Development from 2010 to 2014, Matinas BioPharma Holdings, Inc., as SVP-Clinical Development & Project Management from 2015 to 2017, Knoll Pharmaceutical Co., as Manager-Clinical Research from 1998 to 2000, and Corvidia Therapeutics, Inc., as Senior Vice President-Clinical Operations from 2017 to 2021.
Mr. Kling received his undergraduate degree from Duke University and Masters Business Admin degree from Rutgers Business School.